HSBC Holdings
LEGN icon

HSBC Holdings’s Legend Biotech LEGN Stock Holding History

HSBC Holdings’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-40,994
Closed -$2.75M – 2828
2023
Q3 		$2.75M Buy
+40,994
New +$2.85M ﹤0.01% 1317

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

HSBC Holdings's LEGN Position: Q2 2026 in Review

HSBC Holdings increased its Legend Biotech (LEGN) stake by 6.7% in Q2 2026, buying an estimated $397K and bringing the position to 236,204 shares worth $6.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1100.

HSBC Holdings first reported a position in LEGN in Q4 2021 and has held it in 19 quarters since. The position peaked at $19.3M in Q3 2024. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • HSBC Holdings held 236,204 shares of Legend Biotech worth $6.82M as of Q2 2026.
  • HSBC Holdings bought 14,729 Legend Biotech shares in Q2 2026, an estimated $397K.
  • Legend Biotech made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #1100 holding.
  • HSBC Holdings first reported a position in Legend Biotech in Q4 2021 and has held it in 19 quarters since.
  • HSBC Holdings's Legend Biotech position peaked at $19.3M in Q3 2024.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.